13F Holdings
中文EN

SGP SpyGlass Pharma, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1778922 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.5%
ROA-31.1%
ROIC (approx.)-3,475.3%
Asset turnover—

Leverage & solvency

Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$29.18M$19.98M
SG&A expense$12.27M$7.08M
Operating income-$41.45M-$27.06M
Pretax income-$39.87M-$29.16M
Income tax$0$0
Net income-$39.87M-$29.16M
EBITDA-$40.84M-$26.79M
EPS (basic)-17.98-16.31
EPS (diluted)-17.98-16.31
Weighted avg. shares (diluted)2.22M1.79M
Balance sheet
Cash & equivalents$96.36M$16.27M
Current assets$108.77M$17.41M
PP&E, net$2.34M$2.17M
Total assets$115.87M$23.32M
Current liabilities$8.58M$7.79M
Total liabilities$10.17M$11.25M
Shareholders' equity-$98.84M-$60.47M
Shares outstanding2.20M2.20M
Cash flow statement
Operating cash flow-$32.70M-$22.03M
Capital expenditure$789,000$1.99M
Free cash flow-$33.49M-$24.02M
Investing cash flow-$11.79M$22.26M
Financing cash flow$124.58M$185,000
Depreciation & amortization$612,000$271,000
Stock-based compensation$2.79M$1.49M
Share buybacks$1.45M$0

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.